Trial intelligence / Profile preview

MATCHPOINT: Adoptive T Cell Therapy, DC Vaccines, HSCs, and Pembrolizumab in Recurrent Medulloblastoma

NCT06514898Phase 1Recruiting

Sponsor: University of Florida
Start: May 2025
Primary completion: Sep 2027
Modality: Whole Cell Cancer Vaccines, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 1, open-label, single-arm trial of TTRNA-DC vaccine, TTRNA-xALT, autologous hematopoietic stem cells and pembrolizumab in medulloblastoma, sponsored by University of Florida. Primary endpoints: Dose-Limiting Toxicities up to 12 months and Number of enrolled participants who receive qualified immunotherapy products up to 12 months. Started May 2025; status: recruiting.

Drugs

TTRNA-DC vaccineTTRNA-xALTautologous hematopoietic stem cellspembrolizumab

Conditions

medulloblastoma

Beyond the preview

Go deeper on NCT06514898.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06514898.